[go: up one dir, main page]

MX381342B - Compuestos terapeuticos inhibidores. - Google Patents

Compuestos terapeuticos inhibidores.

Info

Publication number
MX381342B
MX381342B MX2017000450A MX2017000450A MX381342B MX 381342 B MX381342 B MX 381342B MX 2017000450 A MX2017000450 A MX 2017000450A MX 2017000450 A MX2017000450 A MX 2017000450A MX 381342 B MX381342 B MX 381342B
Authority
MX
Mexico
Prior art keywords
therapeutic compounds
compounds
inhibitor therapeutic
useful
inhibition
Prior art date
Application number
MX2017000450A
Other languages
English (en)
Other versions
MX2017000450A (es
Inventor
Andrew Mcdonald
Shawn Qian
Original Assignee
Lifesci Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/072851 external-priority patent/WO2015103317A1/en
Application filed by Lifesci Pharmaceuticals Inc filed Critical Lifesci Pharmaceuticals Inc
Publication of MX2017000450A publication Critical patent/MX2017000450A/es
Publication of MX381342B publication Critical patent/MX381342B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente compuestos derivados heterocíclicos y composiciones farmacéuticas que comprenden dichos compuestos que son útiles para inhibir calicreína de plasma. Adicionalmente, los presentes compuestos y composiciones son útiles para el tratamiento de enfermedades en donde la inhibición de inhibición de calicreína de plasma ha sido implicada, tal como angioedema y similares.
MX2017000450A 2014-07-16 2015-07-15 Compuestos terapeuticos inhibidores. MX381342B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462025203P 2014-07-16 2014-07-16
PCT/US2014/072851 WO2015103317A1 (en) 2013-12-30 2014-12-30 Therapeutic inhibitory compounds
US201562187786P 2015-07-01 2015-07-01
US201562190223P 2015-07-08 2015-07-08
PCT/US2015/040659 WO2016011209A1 (en) 2014-07-16 2015-07-15 Therapeutic inhibitory compounds

Publications (2)

Publication Number Publication Date
MX2017000450A MX2017000450A (es) 2017-08-16
MX381342B true MX381342B (es) 2025-03-12

Family

ID=55079038

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000450A MX381342B (es) 2014-07-16 2015-07-15 Compuestos terapeuticos inhibidores.

Country Status (10)

Country Link
EP (1) EP3169325B1 (es)
JP (2) JP6951970B2 (es)
KR (1) KR102286305B1 (es)
CN (1) CN107072985B (es)
AU (1) AU2015289643B2 (es)
BR (1) BR112017000816A2 (es)
CA (1) CA2954814A1 (es)
EA (1) EA035410B1 (es)
MX (1) MX381342B (es)
WO (1) WO2016011209A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10266515B2 (en) * 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2016011209A1 (en) * 2014-07-16 2016-01-21 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
SG11201809922YA (en) 2016-05-31 2018-12-28 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
GB201703282D0 (en) * 2017-03-01 2017-04-12 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL312036A (en) 2017-11-29 2024-06-01 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibitor
JP2021515761A (ja) * 2018-02-28 2021-06-24 ライフサイ ファーマシューティカルズ，インク． 遺伝性血管浮腫の治療
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
EP4010333A1 (en) * 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
PL4031547T3 (pl) * 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Inhibitory kalikreiny osoczowej i ich zastosowania
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
CN114945566B (zh) 2019-12-06 2024-11-12 沃泰克斯药物股份有限公司 作为钠通道调节剂的取代四氢呋喃
WO2022220608A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법
WO2022220612A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법
IL308953A (en) 2021-06-04 2024-01-01 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0226990B1 (en) * 1985-12-16 1990-03-14 EASTMAN KODAK COMPANY (a New Jersey corporation) Envelopes constructed for ink jet printing
AU2005211349A1 (en) * 2004-01-30 2005-08-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
CA2637620A1 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
AU2007331676A1 (en) 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
WO2009083553A1 (en) 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
JPWO2009119088A1 (ja) * 2008-03-25 2011-07-21 武田薬品工業株式会社 複素環化合物
CA2731196A1 (en) * 2008-07-18 2010-01-21 Takeda Pharmaceuticals Company Limited Benzazepine derivatives and their use as hstamine h3 antagonists
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
US20140378474A1 (en) * 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
AU2013354113B2 (en) * 2012-12-07 2018-03-08 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as CB2 agonists
CA2920815C (en) * 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
WO2015091460A1 (de) * 2013-12-16 2015-06-25 Beko Technologies Gmbh Verfahren zur füllstandsüberwachung in einem sammelraum sowie überwachungsanordnung
US10266515B2 (en) * 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2016011209A1 (en) * 2014-07-16 2016-01-21 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Also Published As

Publication number Publication date
WO2016011209A1 (en) 2016-01-21
CN107072985B (zh) 2020-02-07
KR102286305B1 (ko) 2021-08-09
CA2954814A1 (en) 2016-01-21
JP2020147575A (ja) 2020-09-17
JP2017520597A (ja) 2017-07-27
JP6982343B2 (ja) 2021-12-17
AU2015289643B2 (en) 2020-10-22
AU2015289643A1 (en) 2017-03-02
EA035410B1 (ru) 2020-06-09
KR20170034902A (ko) 2017-03-29
EP3169325A4 (en) 2018-04-11
JP6951970B2 (ja) 2021-10-20
EA201790170A1 (ru) 2017-08-31
CN107072985A (zh) 2017-08-18
MX2017000450A (es) 2017-08-16
BR112017000816A2 (pt) 2017-12-05
EP3169325A1 (en) 2017-05-24
EP3169325B1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MX381342B (es) Compuestos terapeuticos inhibidores.
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
WO2017001926A8 (en) Therapeutic inhibitory compounds
PH12018500899B1 (en) Compositions and methods for inhibiting arginase activity
WO2017001936A3 (en) Therapeutic inhibitory compounds
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691421A1 (ru) Гетероарилы и их применение
MX2016008688A (es) Compuestos terapéuticos inhibidores.
ZA201705749B (en) Substituted pyrazole compounds as serine protease inhibitors
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201591509A1 (ru) Ингибиторы cdc7
MX376207B (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
NZ780408A (en) Human plasma kallikrein inhibitors
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека